when should patients with nhl be referred for car t-cell therapy?
Published 2 years ago • 61 plays • Length 1:23Download video MP4
Download video MP3
Similar videos
-
4:27
the possibility of combining car-t therapy and bispecific antibodies in the treatment of nhl
-
1:55
optimal sequencing of car-t and bispecifics in nhl
-
3:17
safety and activity of cd5 car-t for r/r t-all and t-nhl
-
1:29
cd5.car t-cell therapy in patients with t-cell lymphoma
-
1:45
mosunetuzumab in b-nhl r/r to car-t
-
3:09
car t-cell therapy: side effects
-
7:38
bernadette’s last hope for beating cancer: will car-t cell therapy cure her non-hodgkin's lymphoma?
-
24:06
my refractory non-hodgkin lymphoma treatment: car t-cell therapy & radiation | barbara (2 of 3)
-
1:26
mosunetuzumab in b-nhl r/r to car-t
-
1:50
outcomes of patients with dlbcl following asct and/or car-t
-
2:03
an exciting time for car t-cell therapy: promising results for b-all, nhl and cll
-
0:59
factors to consider by patients regarding car t-cell therapy
-
1:29
outcomes of car-t therapy in patients with refractory b-cell lymphoma
-
3:49
the limitations of immunotherapy with car t-cells
-
1:33
patient selection for car-t in all
-
0:47
outcomes of outpatient tisa-cel recipients with b-nhl
-
4:40
how should cars and bispecifics be selected and sequenced in lbcl?
-
8:57
outcomes of sct in t-all and t-lbl
-
1:41
advances in cellular therapies for lymphoma: the value of car-t therapy & optimizing patient outcome
-
0:58
car-t therapy in non-hodgkin lymphoma: current status and future outlooks
-
2:45
continuity of care for patients with hematological predispositions to aml
-
2:30
car-t as a new standard of care in lymphoma